Treatment of benign prostatic hyperplasia in patients with cardiovascular disease

Drugs and Aging

Volumn 23, Issue 10, 2006, Pages 795-805

  Santillo, Vincent M ^a   Lowe, Franklin C ^a,b,c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; DILTIAZEM; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; HYPOXID ROOPERI EXTRACT; NITRATE; PHENOXYBENZAMINE; PLANT EXTRACT; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SECALE CEREALE EXTRACT; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT; VARDENAFIL;

ABSENCE OF SIDE EFFECTS; ASTHENIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; EJACULATION DISORDER; HUMAN; LIBIDO DISORDER; MALAISE; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SYMPTOMATOLOGY; SYNCOPE;

EID: 33750495394     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623100-00003     Document Type: Review

References (83)

1. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan Jr ED, Wein AJ, editors. Campbell's urology. 8th ed. Philadelphia (PA): Saunders, 2002: 1297-330
2. Lowe FC. Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004 Nov; 26 (11): 1701-13
3. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006 Jan; 28 (1): 13-25
4. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003 Aug; 170 (2 Pt 1): 530-47
5. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984 Sep; 132 (3): 474-9
6. Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am 2002 Feb; 29 (1): 23-9
7. Santillo VS, Lowe FC. Phytotherapeutic agents for the treatment of benign prostatic hyperplasia. AUA Update Series. In press
8. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol 2002 Apr; 19 (6): 426-35
9. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 2002 Jan; 12 (1): 15-8
10. Fitzpatrick JM, Desgrandchamps F. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU Int 2005 Mar; 95 (4): 575-9
11. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published erratum appears in JAMA 2003 Jul 9; 290 (2): 197]. JAMA 2003 May 21; 289 (19): 2560-72
12. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000 Apr; 283 (15): 1967-75
13. McConnell JD, Mahler C, Calais da Dilva F, et al. Endocrine treatment of benign prostatic hyperplasia. In: Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH); 2000 Jun 25-28; Paris. Plymouth: Plymbridge Distributors Ltd, 2001: 425-57
14. Kirby RS, Bryan J, Eardley I, et al. Finasteride in the treatment of benign prostatic hyperplasia: a urodynamic evaluation. Br J Urol 1992 Jul; 70 (1): 65-72
15. Marks LS, Partin AW, Gormley GJ, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol 1997 Jun; 157 (6): 2171-8
16. Marks LS, Partin AW, Dorey FJ, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999 Mar; 53 (3): 574-80
17. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 Apr; 63 (4): 709-15
18. Kaplan SA, Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology 2006 Feb; 67 (2): 225-31
19. Jardin A, Andersson K-E, Chapple C, et al. α1-Adrenoceptor antagonists in the treatment of BPH. In: Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH); 2000 Jun 25-28; Paris. Plymouth: Plymbridge Distributors Ltd, 2001: 461-77
20. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004 Mar; 171 (3): 1029-35
21. Kawabe K. Current status of research on prostate-selective alpha 1-antagonists. Br J Urol 1998 Mar; 81 Suppl. 1: 48-50
22. Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996 Nov; 119 (5): 797-803
23. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999 Feb; 161 (2): 635-40
24. Rudner XL, Berkowitz DE, Booth JV, et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999 Dec; 100 (23): 2336-43
25. Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998 Jun; 159 (6): 1810-5
26. Chon JK, Borkowski A, Partin AW, et al. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999 Jun; 161 (6): 2002-8
27. Partin JV, Anglin IE, Kyprianou N. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer 2003 May 19; 88 (10): 1615-21
28. Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: current clinical experience. Urology 2001 Dec; 58 (6 Suppl. 1): 49-54
29. Roehrborn CG. Three months' treatment with the alpha(1)-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis. Epub 2005 Nov 22
30. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996 Aug 22; 335 (8): 533-9
31. Nieminen T, Ylitalo R, Koobi T, et al. The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. Eur Urol 2005 Mar; 47 (3): 340-5
32. Roehrborn CG. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology 2001 Dec; 58 (6 Suppl. 1): 55-63
33. Weiner DM, Lowe FC. Alfuzosin for the management of benign prostate hyperplasia. Expert Opin Pharmacother 2003 Nov; 4 (11): 2057-63
34. Mottet N, Bressolle F, Delmas V, et al. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol 2003 Jul; 44 (1): 101-5
35. Basar MM, Atan A, Ozergin O, et al. The efficacy of alfuzosin treatment in patients with prostatism. Int Urol Nephrol 2001; 33 (3): 493-7
36. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997 Jul-Aug; 19 (4): 730-42
37. AUA Practice Guidelines Committee. AUA Guideline on the Management of Benign Prostatic Hyperplasia (2003). Chapter 3: Results of the treatment outcomes analyses [online]. Available from URL: http://www.auanet.org/timssnet/ products/guidelines/main_reports/bph_management/chapt_3_appendix.pdf [Accessed 2006 Mar 1]
38. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006 Jan; 28 (1): 13-25
39. Elhilali M, Emberton M, Matzkin H, et al. Long-term efficacy and safety of alfuzosin 10mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2006 Mar; 97 (3): 513-9
40. McKiernan JM, Lowe FC. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J 1997 May; 90 (5): 509-13
41. Narayan P, Lowe FC. The effects of tamsulosin on vital signs in two multicenter, placebo-controlled studies. Cardiovasc Rev Rep 2000; 21: 494-9
42. Lowe FC, Olson PJ, Padley RJ. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology 1999 Jul; 54 (1): 81-5
43. Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther 1999 Oct; 21 (10): 1732-48
44. Kaplan SA, D'Alisera PM. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J Gerontol A Biol Sci Med Sci 1998 May; 53 (3): M201-6
45. Buzelin JM, Fonteyne E, Kontturi M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 1997 Oct; 80 (4): 597-605
46. Lowe FC, Djavan B. Prospective randomized trial to evaluate the side effect profile of tamsulosin versus terazosin in 1983 men with benign prostatic hyperplasia [abstract no. 1052]. J Urol 2002; 167 (4S): 267
47. Nordling J. Efficacy and safety of two doses (10 and 15mg) of alfuzosin or tamsulosin (0.4mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005 May; 95 (7): 1006-12
48. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol 2000 Apr; 163 (4): 1134-7
49. Crawford ED. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU Int 2005 Jun; 95 Suppl. 4: 1-5
50. Souverein PC, Herings RM, de la Rosette JJ, et al. Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. J Clin Epidemiol 2001 May; 54 (5): 518-24
51. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001 Sep; 54 (9): 935-44
52. Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996 Feb; 47 (2): 159-68
53. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994 Jul; 44 (1): 46-51
54. Pool JL. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J 1991 Sep; 122 (3 Pt 2): 926-31
55. Chapple CR, Baert L, Thind P, et al. Tamsulosin 0.4mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 1997; 32 (4): 462-70
56. Michel MC, Bressel HU, Goepel M, et al. A 6-month large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 2001 Jun; 51 (6): 609-14
57. Michel MC, Chapple CR. Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). Eur Urol 2006 Mar; 49 (3): 501-8
58. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 2005 Jun; 95 Suppl. 4: 29-36
59. Flomax® (tamsulosin hydrochloride) capsules [package insert]. 2005 Oct 10 [online]. Available from URL: http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?.docBase=renetnt&folderPath=/ Prescribing+Information/PIs/Flomax+Caps/Flomax.pdf [Accessed 2006 Mar 1]
60. Uroxatral® (alfuzosin hydrochloride) extended-release tablets [package insert]. 2003 Jun [online]. Available from URL: http://products.sanofi- aventis.us/uroxatral/uroxatral.html [Accessed 2006 Mar 1]
61. Hytrin® (terazosin hydrochloride) capsules [package insert]. 2001 Feb [online]. Available from URL: http://www.rxabbott.com/pdf/hytrin.pdf [Accessed 2006 Mar 1]
62. Cardura® (doxazosin mesylate) tablets [package insert]. 2002 Apr [online]. Available from URL: http://www.pfizer.com/pfizer/download/ uspi_cardura.pdf [Accessed 2006 Mar 1]
63. Mikhailidis DP, Khan MA, Milionis HJ, et al. The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000; 16 Suppl. 1: s31-6
64. Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 2003 Aug; 170 (2 Pt 2): S46-50
65. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005 Dec 26; 96 (12B): 42M-6M
66. Viagra® (sildenafil citrate) tablets [package insert]. 2005 Jul [online]. Available from URL: http://pfizer.com/pfizer/download/uspi_viagra.pdf [Accessed 2006 Mar 1]
67. Levitra® (vardenafil hydrochloride) tablets [package insert]. 2005 Jul [online]. Available from URL: http://www.fda.gov/cder/foi/label/2005/ 021400s004lbl.pdf [Accessed 2006 Mar 1]
68. Cialis® (tadalafil) tablets [package insert]. 2005Aug 26 [online]. Available from URL: http://pi.lilly.com/us/cialis-pi.pdf [Accessed 2006 Mar 1]
69. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992 Oct 22; 327 (17): 1185-91
70. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349 (25): 2387-98
71. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995 Nov; 154 (5): 1770-4
72. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 Sep; 60 (3): 434-41
73. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003 Jan; 61 (1): 119-26
74. Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998 Sep; 34 (3): 169-75
75. Proscar® (finasteride) tablets [package insert]. 2006 Jan [online]. Available from URL: http://www.proscar.com/proscar/shared/documents/proscar_pi. pdf [Accessed 2006 Mar 1]
76. Avodart® (dutasteride) soft gelatin capsules [package insert]. 2005 May [online]. Available from URL: http://us.gsk.com/products/assets/us_avodart. pdf [Accessed 2006 Mar 1]
77. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003 Feb; 61 (2): 354-8
78. Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003 Apr; 61 (4): 791-6
79. Vaughan Jr ED. Medical management of benign prostatic hyperplasia: are two drugs better than one? N Engl J Med 2003 Dec 18; 349 (25): 2449-51
80. Boyle P, Robertson C, Lowe F, et al. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 2004 Apr; 93 (6): 751-6
81. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006 Feb 9; 354 (6): 557-66
82. Glemain P, Coulange C, Billebaud T, et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [in French]. Prog Urol 2002 Jun; 12 (3): 395-403
83. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002 May; 41 (5): 497-506